Hepatitis B: can GSK’s bepirovirsen deliver functional cure?
GSK’s antisense oligonucleotide is looking to further prove its value in disrupting viral replication via a Phase III test.
By
Gastrointestinal
Latest in
Gastrointestinal
MediciNova begins Phase II non-alcoholic fatty liver disease trial
The Phase II trial will assess MN-001’s safety and efficacy to treat NAFLD patients with T2DM, and hypertriglyceridemia.
CANbridge doses first subject in Phase II biliary atresia trial in China
An international Phase II trial, EMBARK will analyse the safety and efficacy of maralixibat to treat BA patients.
Beyond biopsy: how noninvasive NASH tests can move the needle
There are a variety of noninvasive NASH tests currently available and under investigation—but how can they be optimised?
By
Inventiva begins screening in NASH and type-2 diabetes Phase IIa study
Inventiva begins participant screening in NASH and type-2 diabetes treatment study
Innovent Phase II ulcerative colitis antibody trial doses first subject
The trial is assessing the safety and efficacy of IBI112 to treat moderate-to-severe active UC.
Kezar reports positive Phase II data of zetomipzomib for lupus nephritis
In the trial, 64.7% of the trial subjects attained an ORR, which is the primary efficacy endpoint of the study.
Pipeline Moves: Corcept’s Phase III pancreatic ductal adenocarcinoma trial termination leads to approval shot dive
The Clinical Trials Arena team also review studies in liver disease, venous leg ulcer, sleep apnoea, and ocular issues.
By